Clinical trials: Soft-Tissue Sarcoma, open to volunteers
- Condition Soft-Tissue Sarcoma
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Relapsed / Refractory Osteosarcoma
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma.
- Trial name
- NCT07357519
- Testing
- LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Lantheus Medical Imaging
Sarcoma
Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle.
- Trial name
- NCT06126510
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.
Soft Tissue Sarcoma
Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study
Generally, specific demographic cohorts exhibit higher participation rates in medical research, yet there exists a scarcity of research elucidating the trial attributes impacting the engagement of these particular demographics.
- Trial name
- NCT06264505
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Soft Tissue Sarcoma
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
soft tissue sarcoma
- Trial name
- NCT07920835
- Testing
- 68Ga-HX01 Injection Solution
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd
Ewing Sarcoma
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric…
- Trial name
- NCT07297979
- Testing
- Xaluritamig
- Where
- 13 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Liposarcoma, Advanced Solid Tumor
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Part 1 is a phase Ib standard "3 + 3" design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors.
- Trial name
- NCT04785196
- Testing
- APG-115, Toripalimab
- Where
- 3 sites in China
- Volunteers
- 95 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Sarcoma, Metastatic Sarcoma
Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients
The objective of this prospective study is to capture the quality of life of patients with locally advanced or metastatic sarcoma, and investigate the effectiveness of support provided through a personalized web-based platform.
- Trial name
- SARC-Digital (NCT07642375)
- Testing
- Digital support
- Where
- 11 sites in Greece
- Volunteers
- 108 people
- Sponsor
- CareAcross
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1
- Trial name
- NCT05735184
- Testing
- Ziftomenib, Venetoclax, Azacitidine
- Where
- 44 sites in United States
- Volunteers
- 420 people
- Sponsor
- Kura Oncology, Inc.
Sarcoma, Ewing, Chondrosarcoma
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
This prospective, multi-center, randomized controlled study aims to assess the efficacy of utilizing 3D printed models in preoperative planning for the excision of tumors involving bony structures within the body.
- Conditions
- Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma
- Trial name
- NCT06387485
- Testing
- 3D Printed Anatomic Model, CT/MRI
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ricoh USA, Inc.
Soft Tissue Sarcoma (STS), Utidelone
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
This trial is an open, multicenter, phase II clinical trial evaluating the efficacy and safety of uterostatin capsules (UTD2) combined with doxorubicin and tislelizumab in the treatment of advanced soft tissue sarcoma.
- Conditions
- Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin
- Trial name
- NCT07842276
- Testing
- UTD2 + tislelizumab + doxorubicin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma
Evaluate the Safety and Clinical Activity of HH2853
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II.
- Conditions
- FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
- Trial name
- NCT04390737
- Testing
- HH2853 Tablets
- Where
- 25 sites in United States, China
- Volunteers
- 254 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Synovial Sarcomas
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
- Trial name
- NCT07174427
- Testing
- TBI-1301, Cyclophosphamide, Fludarabine
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Takara Bio Inc.
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06700070
- Testing
- PBA-0111
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pure Biologics S.A.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.